Glenmark Pharmaceuticals Limited and Torrent Pharmaceuticals Limited have announced the signing up of a licensing agreement for co-marketing diabetes drug Remogliflozin Etabonate in India. In terms of the agreement, Glenmark will get an upfront payment, licence fees and royalties for the non-exclusive sub-licence rights from Torrent.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.